Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients
- 24 July 2012
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 19 (13) , 4052-4058
Abstract
Epithelial ovarian carcinoma is the main cause of death from gynaecological cancers in the western world. The initial response rate to the frontline therapy is high. However, the prognosis of persistent and recurrent disease remains poor. During the two past decades, a new therapeutic approach to peritoneal carcinomatosis has been developed, combining maximal cytoreductive effort with hyperthermic intraperitoneal chemotherapy (HIPEC). A retrospective, multicentric study of 246 patients with recurrent or persistent ovarian cancer, treated by cytoreductive surgery and HIPEC in two French centers between 1991 and 2008, was performed. An optimal cytoreductive surgery was possible in 92.2 % of patients. Mortality and morbidity rates were 0.37 % and 11.6 %, respectively. The overall median survival was 48.9 months. There was no significant difference in overall survival in patients with persistent or recurrent disease. In multivariate analysis, performance status was a significant prognostic factor in patients with extensive peritoneal carcinomatosis (peritoneal cancer index >10). Salvage therapy combining optimal cytoreductive surgery and HIPEC is feasible and may achieve long-term survival in highly selected patients with recurrent ovarian carcinoma, including those with platinum resistant disease, with acceptable morbidity.Keywords
This publication has 46 references indexed in Scilit:
- Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapyCancer, 2010
- Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French StudyJournal of Clinical Oncology, 2010
- Cytoreductive surgery for recurrent ovarian cancer: A meta-analysisGynecologic Oncology, 2009
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?The Lancet Oncology, 2006
- Cancer of the OvaryNew England Journal of Medicine, 2004
- Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based studyAmerican Journal of Obstetrics and Gynecology, 2004
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-AnalysisJournal of Clinical Oncology, 2002
- A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA)Gynecologic Oncology, 1993
- Recurrence after negative second-look laparotomy for ovarian cancer: Analysis of risk factorsAmerican Journal of Obstetrics and Gynecology, 1988